Abstract | OBJECTIVE: METHODS: Fifty-six patients with mild asthma were randomly divided into treatment group (n=41) receiving oral theophylline at daily dose of 4 to 6 mg/kg for 16 weeks and control group (15 cases) without medication other than beta2 antagonist, which was administered when necessary in both groups. Peripheral blood T-lymphocyte subsets (CD3(+), CD4(+), and CD8(+)) and pulmonary function (PEF(am) and PD(20)) before and at 8 and 16 weeks during treatment were measured. RESULTS: Significant difference was observed in CD3+ and CD4(+) T-lymphocyte subsets after medication with theophylline (P<0.05) in the patients, and PEF(am) and PD(20) were also significantly different from those of the control group (P<0.05). Theophylline significantly improved the clinical symptom scores (P<0.05) and decreased the asthma attacks. CONCLUSION:
|
Authors | Shao-dan Huang, Jun Yang, Shi-ye Zhang, Li-qi Tian, Qiao-hong Pan |
Journal | Nan fang yi ke da xue xue bao = Journal of Southern Medical University
(Nan Fang Yi Ke Da Xue Xue Bao)
Vol. 26
Issue 3
Pg. 325-7
(Mar 2006)
ISSN: 1673-4254 [Print] China |
PMID | 16546738
(Publication Type: English Abstract, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Bronchodilator Agents
- Theophylline
|
Topics |
- Administration, Oral
- Adult
- Asthma
(drug therapy, immunology, physiopathology)
- Bronchodilator Agents
(administration & dosage, therapeutic use)
- Female
- Humans
- Male
- Middle Aged
- Respiratory Function Tests
- T-Lymphocyte Subsets
(drug effects, immunology)
- Theophylline
(administration & dosage, therapeutic use)
- Treatment Outcome
|